Chen, Young K.,Kanouni, Toufike,Kaldor, Stephen W.,Stafford, Jeffrey Alan,Veal, James Marvin,Tavares-Greco, Paula Alessandra,Kreilein, Matthew Michael
申请号：
AU2016349707
公开号：
AU2016349707A1
申请日:
2016.11.04
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the lysine specific demethylase-1 inhibitor 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluorobenzonitrile. Also described are pharmaceutical compositions suitable for administration to a mammal that include the lysine specific demethylase-1 inhibitor, and methods of using the lysine specific demethylase-1 inhibitor for treating diseases or conditions that are associated with lysine specific demethylase-1 activity.
